| Literature DB >> 34746867 |
Roger S Zou1, Yang Liu2, Taekjip Ha1,2,3,4.
Abstract
The ability to deactivate CRISPR-Cas systems on demand would improve the safety and applicability of genome editing. Here, we detail a protocol using photocleavable guide RNAs (pcRNAs) to deactivate CRISPR-Cas9 inside cells. We verify that deactivation is both rapid and complete by checking for insertion-deletion (indel) mutations using Sanger sequencing. This protocol will be useful for researchers interested in using pcRNAs to improve genome editing specificity, characterize the timescales of genome editing, and study cellular DNA damage responses. For complete details on the use and execution of this protocol, please refer to Zou et al. (2021).Entities:
Keywords: Biotechnology and bioengineering; CRISPR; Cell Biology; Cell-based Assays; Genomics; Molecular Biology; Molecular/Chemical Probes; Sequencing
Mesh:
Substances:
Year: 2021 PMID: 34746867 PMCID: PMC8551926 DOI: 10.1016/j.xpro.2021.100909
Source DB: PubMed Journal: STAR Protoc ISSN: 2666-1667
Synthetic DNA sequences
| Name | Sequence (5′ to 3′) |
|---|---|
| TracrRNA | AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUG |
| Pcl5_HEKsite4 | GGCAC/iPC-Linker/GCGGCUGGAGGUGGGUUUUAGAGCUAUGCUGUUUUG |
| gRNA_HEKsite4 | GGCACTGCGGCTGGAGGTGGGUUUUAGAGCUAUGCU |
| HEKs4_F | CCAGTGGTTCAATGGTCATCC |
| HEKs4_R | GGCCAGTGAAATCACCCTG |
Figure 1Cas9 electroporation protocol into HEK293T cells
(A) Individual reagents necessary for electroporation, including Cas9/pcRNA RNP, EP enhancer, SF mix, and cuvette.
(B) Dissociating the cells using Trypsin, and the cells after mixing to the required single cell suspension before electroporation.
(C) After pelleting single cell suspension and resuspending in 1 mL PBS.
(D) After mix cell pellet with RNP solution.
(E) Electroporation settings on the Lonza electroporator.
(F) Beginning the electroporation after placing the cuvette in the machine.
(G) Zoom-in of the cuvette placement in the holder from panel f. Note the visible yellow pin that is visible only with the correct orientation (red box).
(H) Screen display a successful electroporation.
Organization of cell samples after electroporation
| Well A | Well B | Well C |
|---|---|---|
| Light right after delivery | Light 1 h after delivery | No light applied |
| Indels measured at 3 days | Indels measured at 3 days | Indels measured at 3 days |
Figure 2Light illumination for deactivation of Cas9/pcRNA
(A) Sample A has 50 μL of PBS. Sample B and C have 50 μL PBS + 300 μL DMEM complete.
(B) Sample A is illuminated by the LED flashlight for 1 min. The flashlight is balanced and centered on the well. To avoid unintended illumination of multiple wells, we suggest separating each well into different 48-well plates. For this protocol, multiple wells were used in the same plate for ease of presentation in the figure.
(C) Cells in Sample A one hour after electroporation and light illumination. Cells are healthy and already adhering to the well. Scale bar corresponds to 100 μm.
Figure 3Sanger sequencing and indel measurement
(A) Sanger sequencing traces around the Cas9 target site for cells exposed to Cas9 followed by light right after electroporation (‘light 1m’), cells exposed to Cas9 but no light (‘no light), or cells without Cas9 exposure (‘neg ctrl’). 2.0%, 68.5%, 1.7% correspond to the estimated indel percentage at 3 days after electroporation for each sample.
(B) Output of TIDE indel analysis for cells exposed to Cas9 but no light (‘no light’).
(C) Output of TIDE indel analysis for cells exposed to Cas9 followed by light right after electroporation (‘light 1m’).
(D) Quantification of indel percentage at 3 days after electroporation for the samples described in panel a. Quantification for cells exposed to Cas9 followed by light at 1 h after electroporation is also included (‘light 1h’).
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Alt-R® S.p. Cas9 Nuclease V3 | Integrated DNA Technologies | Cat#1081059 |
| IDTE pH 8.0 (1 | Integrated DNA Technologies | Cat#11-05-01-13 |
| Nuclease Free Duplex Buffer | Integrated DNA Technologies | Cat#11-01-03-01 |
| Corning™ DMEM with L-Glutamine, Glucose, Sodium Pyruvate | Fisher Scientific | Cat#MT10013CV |
| Corning™ Regular Fetal Bovine Serum | Fisher Scientific | Cat#MT35011CV |
| Penicillin-Streptomycin | Thermo Fisher Scientific | Cat#15070063 |
| 3 M Sodium Acetate | Thermo Fisher Scientific | Cat# R1181 |
| Trypsin-EDTA (0.05%), phenol red | Thermo Fisher Scientific | Cat#25300062 |
| Collagen I, rat tail | Thermo Fisher Scientific | Cat#A1048301 |
| SF Cell Line 4D-Nucleofector™ X Kit S (32 RCT) | Lonza | Cat#V4XC-2032 |
| DNeasy Blood & Tissue Kit (50) | QIAGEN | Cat#69504 |
| QIAquick PCR Purification Kit (50) | QIAGEN | Cat#28104 |
| Q5® Hot Start High-Fidelity 2 | New England BioLabs | Cat#M0494 |
| E-Gel™ EX Agarose Gels, 2% | Invitrogen | Cat#G402022 |
| Human: HEK293T | ATCC | Cat#CRL-3216 |
| Alt-R® CRISPR-Cas9 crRNA (sequence ‘gRNA_HEKsite4’ in | Integrated DNA Technologies | N/A |
| Alt-R® CRISPR-Cas9 tracrRNA, 100 nmol | Integrated DNA Technologies | Cat#1072534 |
| Alt-R® Cas9 Electroporation Enhancer, 10 nmol | Integrated DNA Technologies | Cat#1075916 |
| tracrRNA (sequences in | Integrated DNA Technologies | N/A |
| photocleavable crRNA (sequence ‘Pcl5_HEKsite4’ in | Integrated DNA Technologies | N/A |
| HEKs4_F (sequences in | Integrated DNA Technologies | N/A |
| HEKs4_R (sequences in | Integrated DNA Technologies | N/A |
| SnapGene Viewer | SnapGene | |
| TIDE | ||
| Original/source data in the paper is available | This paper | Mendeley Data |
| 4D-Nucleofector Core Unit | Lonza | Cat#AAF-1002B |
| 4D-Nucleofector X Unit | Lonza | Cat#AAF-1002X |
| Nalgene™ Rapid-Flow™ Sterile Single Use Vacuum Filter Units | Thermo Fisher Scientific | Cat#09-741-02 |
| Standard Hemocytometer | Weber Scientific | Cat#3048-12 |
| C1000 Touch Thermal Cycler | Bio-Rad | Cat#1851148 |
| Aluminum Foil | N/A | N/A |
| LED flashlight | JAXMAN | Cat#B06XW7S1CS ( |
| NanoDrop™ 2000 UV-Vis spectrophotometer | Thermo Fisher Scientific | Cat#ND-2000 |
| E-Gel® iBase™ Power System with E-Gel™ Safe Imager™ Real-Time Transilluminator | Invitrogen | Cat#G6465 |
DMEM complete
| Reagent | Final concentration | Amount |
|---|---|---|
| DMEM | 89% | 445 mL |
| Fetal Bovine Serum (FBS) | 10% | 50 mL |
| Penicillin-Streptomycin | 1% | 5 mL |
Store in 4°C, maximum time of 1 year.
| Component | Volume |
|---|---|
| Annealed gRNA (50 μM) | 2.4 μL |
| Cas9 (10 mg/mL) | 1.7 μL |
| PBS | 1.9 μL |
| Component | Volume |
|---|---|
| Nuclease Free Water (NFW) | 3 μL |
| Genomic DNA (10–50 ng) | 1 μL |
| Fwd/Rev primer set (5 μM) | 1 μL |
| Q5® High-Fidelity 2 | 5 μL |
| PCR cycling conditions | |||
|---|---|---|---|
| Steps | Temperature | Time | Cycles |
| Initial Denaturation | 98°C | 30 s | 1 |
| Denaturation | 98°C | 10 s | 35 cycles |
| Annealing | 68°C | 10 s | |
| Extension | 72°C | 20 s | |
| Final extension | 72°C | 2 min | 1 |
| Hold | 4°C | Forever | |